Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ficolin-2 (FCN2), also known as L-ficolin, is a pattern recognition receptor of the innate immune system, encoded by the FCN2 gene and secreted mainly by the liver into serum. It consists of a collagen-like stalk and a C-terminal fibrinogen-like domain; this multimeric lectin binds specifically to acetylated carbohydrate structures on microbial surfaces such as lipoteichoic acid of Gram-positive bacteria. Upon binding, Ficolin-2 assembles with MBL-associated serine proteases (MASPs), thereby activating the lectin pathway of the complement cascade and promoting opsonization and phagocytosis of pathogens. Ficolin-2 interacts with other humoral molecules (e.g., pentraxin 3) to enhance complement deposition on pathogens. Genetic polymorphisms in FCN2 significantly impact Ficolin-2 serum levels, potentially altering individual susceptibility to infectious diseases.
Ligand recognition triggers assembly with MBL-associated serine proteases (MASPs), leading to complement activation and opsonization of pathogens
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ficolin-2 (FCN2).